Despite the unprecedented Ebola virus outbreak response in West Africa, no Ebola 
medical countermeasures have been approved by the US Food and Drug 
Administration. However, multiple valuable lessons have been learned about the 
conduct of clinical research in a resource-poor, high risk-pathogen setting. 
Numerous therapeutics were explored or developed during the outbreak, including 
repurposed drugs, nucleoside and nucleotide analogues (BCX4430, brincidofovir, 
favipiravir, and GS-5734), nucleic acid-based drugs (TKM-Ebola and AVI-7537), 
and immunotherapeutics (convalescent plasma and ZMapp). We review Ebola 
therapeutics progress in the aftermath of the West Africa Ebola virus outbreak 
and attempt to offer a glimpse of a path forward.